Lux Capital
Lux Capital is a venture capital firm focused on emerging science and technology ventures. They specialize in deep tech and life sciences, backing companies that are turning science fiction into fact, including breakthrough biotechnology, drug discovery, and healthcare technology.
Website
https://www.luxcapital.comLocation
New York, New York, USA
Founded
2000
AUM
$5B+
Investment Range
$1M - $100M+
Portfolio Companies
2
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth
Investment Thesis
Lux Capital invests in companies that are harnessing scientific breakthroughs to solve hard problems. In life sciences, they focus on next-generation drug discovery platforms, novel therapeutic modalities, and technologies that fundamentally change how we understand and treat disease.
Team
Partners / Managing Directors (Health & Bio Focus)
- Josh Wolfe - Co-Founder & Managing Partner
- Zavain Dar - Partner
- Deena Shakir - Partner
- Shahin Farshchi, PhD - Partner
Other Key Team Members
- Peter Hébert - Co-Founder & Managing Partner
- Bilal Zuberi - Partner
Focus Areas
- Drug discovery platforms
- Biotechnology
- Synthetic biology
- Computational biology
- Deep tech in healthcare
- Healthcare AI
- Novel therapeutic modalities
Notable Exits
- Desktop Metal - SPAC (2020)
- Shapeways - SPAC (2021)
- Eikon Therapeutics - Continuing ($350.7M Series D, February 2025)
Notable Healthcare Investments
- Eikon Therapeutics - Drug discovery platform
- Recursion - AI drug discovery
- Variant Bio - Population genomics
Sources
- https://www.luxcapital.com
- https://www.luxcapital.com/team
- PitchBook
- Crunchbase
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Eikon Therapeutics | Hayward, California, USA | 2019 | drug-discoveryai-drug-discovery+3 |
| Maven Clinic | New York, New York, USA | 2014 | healthcare-platformdigital-health+3 |